Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brontictuzumab + Chemotherapy in Metastatic Colorectal Cancer
NCT03031691Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brontictuzumab in metastatic colorectal cancer (mCRC), sponsored by OncoMed Pharmaceuticals. Primary endpoints: Percentage of patients with adverse events up to 2 years, Percentage of patients with dose limiting toxicities at 28 days and 1 more. Started Jan 2017; status: completed.
02
Drugs
brontictuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03031691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031691.